Trial Search Results

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Procedure: Assessment of Therapy Complications
  • Other: Questionnaire Administration




Inclusion Criteria:

   - The patient must be enrolled on a frontline COG therapeutic trial for treatment of a
   primary malignancy and is nearing completion of or has recently completed protocol
   treatment (within the past 180 days)*; or the patient must have been enrolled on a COG
   (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term
   follow-up by ALTE05N1

      - Hodgkin lymphoma

         - CCG-5942

         - POG-9425

         - POG-9426

         - COG-AHOD0031

      - Brain tumor

         - CCG-A9961

      - Acute lymphoblastic leukemia

         - POG-9404

      - Rhabdomyosarcoma

         - IRS-III

         - IRS-IV

      - Note: For purposes of enrollment onto this study, completion of treatment is
      defined as the date protocol therapy was terminated as reported (or will be
      reported) on this patient's last "Reporting Period Worksheet/CRF" for their
      frontline therapeutic protocol; patients become eligible as they approach this
      date, and remain eligible for 180 days following the date that protocol therapy
      was terminated; early termination of protocol therapy per the decision of the
      patient, family and/or investigator does NOT preclude enrollment on this study

      - Note: For purposes of eligibility for ALTE05N1, "early termination of protocol
      therapy" means that the patient has finished protocol therapy and will not
      receive further treatment; patients whose therapy is terminated early due to
      toxicity or who opt out of an end-of-therapy randomization (e.g., randomization
      to continue with an experimental agent vs. no further treatment) are eligible
      because they will not be receiving further therapy; however, a patient who is
      removed from protocol therapy or opts to discontinue protocol participation early
      in the course of treatment (e.g., following Induction) is not eligible

   - The patient must reside in the U.S. on the date of enrollment to ALTE05N1

   - All patients and/or their parents or legal guardians must sign a written informed

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christina Baggott